However, because TNBC is often classified as a “cold” tumor that poses challenges for immune cell infiltration, the application of ICB therapy for TNBC is still limited, and only a small proportion of TNBC patients can benefit from anti-PD-1/PD-L1 therapy [39, 40]. This evidence concerns the gene PDCD1 and neoplasm.